Scotiabank raised the firm’s price target on Sabra Health Care to $18 from $17 and keeps a Sector Perform rating on the shares. After strong Q3 outperformance by U.S. REITs, the firm remains constructive on the sector, but also sees current valuation as already pricing in much of the benefit from lower interest rates, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA:
- Sabra Health Care upgraded to Overweight from Equal Weight at Wells Fargo
- Sabra Health Care upgraded to Buy from Neutral at Citi
- Sabra Health Care price target raised to $18 from $16 at Truist
- Sabra Health Care price target raised to $17 from $15 at Scotiabank
- Sabra Health Care price target raised to $16 from $14 at Wells Fargo